

References

- Abay, S.M. and Amelo, W. (2010). Assessment of self-medication practices among medical, pharmacy, and health science students in Gondar University, Ethiopia. *J Young Pharmacists*. 2: 306-10.
- Abraham, D.J. (2003). Quinolone, in Burger's Medicinal Chemistry Drug Discovery. John Wiley and Sons, Hoboken, New Jersey. p. 582- 587.
- Acar, J.F. and Goldstein, F.W. (1997). Trends in bacterial resistance to fluoroquinolones. *Clin Infect Dis*. 24 (Suppl 1): S67-73. http://dx.doi.org/10.1093/clinids/24.Supplement_1.S67
- Ahmed, M., Lyass, L., Markham, P.N., Taylor, S.S., Vasquez- Laslop, N. and Neyfakh, A.A. (1995). Two highly similar multidrug transporters of *Bacillus subtilis* whose expression is differentially regulated. *Jl of Bacteriol*. 177: 3904-10.
- Ahmed, A.M., Motoi, Y., Sato, M., Maruyama, A., Watanabe, H., Fukumoto, Y. and Shimamoto. T. (2007). Zoo animals as reservoirs of gram-negative bacteria harboring integrons and antimicrobial resistance genes. *Appl. Environ. Microbiol*. 73: 6686-6690.
- Ajjj, M., Paul, D. and Bhattacharjee, A. (2015). Carriage of quinolone resistance in faecal coliforms among healthy individuals: A study from northeast India. *Indian Jour Med Microbiol*. 33(1): 190-191.
- Alekshun, M.N. and Levy, S.B. (1997). Regulation of chromosomally mediated multiple antibiotic resistance: the *mar* regulon. *Antimicrob Agents Chemother*. 41: 2067-75.
- Ali, I., Rifaque, Z., Ahmed, S., Malik, S. and Dasti, J.I. (2016). Prevalence of multi-drug resistant uropathogenic *Escherichia coli* in Potohar region of Pakistan. *Asian Pac J Trop Biomed*. 6(1): 60-66.
- Al-Agamy, M.M., Shibl, A.M. and Radwan. H.H. (2012). Detection of mutation in quinolone resistant determining regions in clinical isolates of *Escherichia coli* from Saudi Arabia. *Afr. J of Biotechnology*. 11(5): 1054-1058.

- Al-Marzooq, F., Yasim, M., Yusof, M. and Tay, S.T. (2014). Molecular Analysis of Ciprofloxacin Resistance Mechanisms in Malaysian ESBL-Producing *Klebsiella pneumoniae* Isolates and Development of Mismatch Amplification Mutation Assays (MAMA) for Rapid Detection of *gyrA* and *parC* Mutations. *BioMed Res Int*. Article ID 601630, 10 pages.
- Alonso, A. and Martínez, J. L. (1997). Multiple antibiotic resistance in *Stenotrophomonas maltophilia*. *Antimicrob Agents and Chemother*. 41: 1140–2.
- Amábile-Cuevas, C.F., Arredondo-García, J.L., Cruz, A., Rosas, I. (2010). Fluoroquinolone resistance in clinical and environmental isolates of *Escherichia coli* in Mexico City. *J Appl Microbiol*. 108: 158-162.
- Ambrozic Avgustin, J., Keber, R., Zerjavic, K., Orazem, T. and Grabnar, M. (2007). Emergence of the quinolone resistance-mediating gene *aac(6′)-Ib-cr* in extended-spectrum β lactamase-producing *Klebsiella* isolates collected in Slovenia between 2000 and 2005. *Antimicrob. Agents Chemother*. 51:4171– 4173.
- Anquetin, G., Greiner, J. and Mahmoud, N. (2006). Design, synthesis and activity against *Toxoplasma gondii*, *Plasmodium* spp., and *Mycobacterium tuberculosis* of new 6-fluoroquinolones. *Eur. J. Med. Chem*. 41(12): 1478–149.
- Appelbaum, P.C. and Hunter, P.A. (2000). The fluoroquinolone antibacterials: past, present and future perspectives. *Int. J. Antimicrob. Agents*. 16: 5–15
- Arsene, S. and Leclercq. R. (2007). Role of a *qnr*-like gene in the intrinsic resistance of *Enterococcus faecalis* to fluoroquinolones. *Antimicrob. Agents Chemother*. 51: 3254–3258.
- Awad, A., Eltayeb, I. and Matowe, L. (2005). Self-medication with antibiotics and antimalarials in the community of Khartoum State, Sudan. *J Pharm Pharm Sci*. 8(2): 326-31.
- Azmi, I.J., Khajanchi, B.K., Akter, F., Hasan, T.N., Shahnaij, M., et al. (2014). Fluoroquinolone Resistance Mechanisms of *Shigella flexneri* Isolated in Bangladesh. *PLOS ONE*. 9(7): e102533.

- Bachoual, R., Ouabdesselam, S., Mory, F., Lascols, C., Soussy, C.-J. and Tankovic, J. (2001). Single or double mutational alterations of GyrA associated with fluoroquinolone resistance in *Campylobacter jejuni* and *Campylobacter coli*. *Microb Drug Resist.* 7(3): 257-61.
- Bae, D.H., Baek, H.J., Jeong, S.J. and Lee, Y.J. (2013). Amino acid substitutions in gyrA and parC associated with quinolone resistance in nalidixic acid-resistant *Salmonella* isolates. *Ir. Vet. J.* 66(1): 23
- Bagel, S., Hullen, V. and Wiedemann, B. (1999). Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of *Escherichia coli*. *Antimicrob Agents Chemother.* 43: 868–875.
- Baquirin, M.H., and Barlow, M. (2008). Evolution and recombination of the plasmidic *qnr* alleles. *J. Mol. Evol.* 67: 103–110.
- Barker, K. (2005). *At the bench: a laboratory Navigator*. Updated edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York.
- Barnard, F.M. and Maxwell, A. (2001). Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). *Antimicrob Agents Chemother.* 45: 1994-2000.
- Barton, N., Crowther, A.F., Hepworth, W., Richardson, D.N. and Driver, G.W. (1961). New quinolones and therapeutic compositions containing them. *GB 830832* (1960) [*Chem. Abstr.* 55: 7442e]
- Batt, A.L., Bruce, I.B. and Aga, D.S. (2006). Evaluating the vulnerability of surface waters to antibiotic contamination from varying wastewater treatment plant discharges. *Environ. Pollut.* 142: 295–302.
- Blondeau, J.M. (1999). Expanded activity and utility of the new fluoroquinolones: a review. *Clin. Ther.* 21: 3.
- Bonemann, G., Stiens, M., Puhler, A. and Schluter, A. (2006). Mobilizable IncQ- related plasmid carrying a new quinolone resistance gene, *qnrS2*, isolated from the bacterial community of a water treatment plant. *Antimicrob. Agents Chemother.* 50: 3075- 3080.
- Bouchakour, M., Zerouali, K., Claude, J., Amarouch, H., Mdaghri, N., Courvalin, P. and Mohammed, T. (2010). Plasmid-mediated quinolone

resistance in expanded spectrum beta lactamase producing *Enterobacteriaceae* in Morocco. *J Infect Dev Ctries.* 4(12): 799-803.

- Boucher, Y., Labbate, M., Koeing, J.E. and Stokes, H.W. (2007). Integrons: mobilizable platform that promote genetic diversity in bacteria. *Trends Microbiol.* 15: 301-309.
- Baucheron, S., Chaslus-Dancla, E., Cloeckert, A., Chiu, C.H. and Butaye, P. (2005). High-level resistance to fluoroquinolones linked to mutations in *gyrA*, *parC*, and *parE* in *Salmonella enterica* serovar Schwarzengrund isolates from humans in Taiwan. *Antimicrob. Agents Chemother.* 49:862-863.
- Bouchillon, S., Hoban, D.J., Badal, R., and Hawser, S. (2012). Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010. *The Open Microbiology Journal.* 6: 74-78.
- Boyd, D.A., Tyler, S., Christianson, S., McGeer, A., Muller, M.P., Willey, B.M., Bryce, E., Gardam, M., Nordmann, P. and Mulvey, M.R. (2004). Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob. Agents Chemother.* 48: 3758–3764.
- Bratzler, D.W., Dellinger, E.P., Olsen, K.M., Perl, T.M., Auwaerter, P.G., Bolon, M.K., Fish, D.N., Napolitano, L.M., Sawyer, R.G., Slain, D., Steinberg, J.P. and Weinstein, R.A. (2013). American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm.* 70: 195-283.
- Breines, D.V., Ouabdesselam, S., Ng, E. Y., Tankovic, J., Shah, S. and Soussy, C. J. (1997). Quinolone resistance locus *nfxD* of *Escherichia coli* is a mutant allele of the *parE* gene encoding a subunit of Topoisomerase IV. *Antimicrob Agents and Chemother.* 41: 175–9.

- Brighty, K.E. and Gootz, T.D. (1997). The chemistry and biological profile of trovafloxacin. *J. Antimicrob. Chemother.* 39 (Suppl. B): 1–14
- Brisse, S., Milatovic, D., Fluit, A.C., Verhoef, J., Martin, N., Scheuring, S., Kohrer, K. and Schmitz, F. (1999). Comparative In Vitro Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Enterobacter cloacae*, and *Enterobacter aerogenes* Clinical Isolates with Alterations in GyrA and ParC Proteins. *Antimicrob. Agents and Chemother.* 43(8): 2051-2055.
- Cambau, E., Lascols, C., Sougakoff, W., Bebear, C., Bonnet, R., Cavallo, J.D., Gutmann, L., Ploy, M.C, Jarlier, V., Soussy, C.J. and Robert J. (2006). Occurrence of *qnr* A positive clinical isolates in French teaching hospitals during 2002-2005. *Clin. Microbiol. Infect.* 12: 1013-1020.
- Campos, J., Gil, J., Mourao, J., Peixe, L. and Antunes, P. (2015). Ready to eat street- vended food as a potential vehicle of bacterial pathogens and antimicrobial resistance: An exploratory study in Porto region, Portugal. *Int. Journal of Food Microbiology.* 206: 1-6.
- Cano, M.E., Rodríguez-Martínez, J. M., Agüero, J., Pascual, A., Calvo, J., García-Lobo, J. M., Velasco, C., Francia, M.V. and Martínez-Martínez, L. (2009). Detection of Plasmid-mediated quinolone resistance genes in clinical isolates of *Enterobacter* spp. in Spain. *J. Clin. Microbiol.* 47(7): 2033-2039.
- Caratolli, A. (2011). Plasmids in Gram negatives: molecular typing of resistance plasmids. *Int. J. Medical Microbiol.* 301: 654-658.
- Caratolli, A., Bertini, A., Villa, L., Falbo, V., Hopkins, K.L. and Threlfall, E.J. (2005). Identification of plasmids by PCR based replicon typing. *J Microbiol. Methods.* 63: 219-228.
- Castanheira, M., Mendes, R. E. , Rhomberg, P. R. and Jones, R. N. (2008). Rapid emergence of *bla*CTX-M among *Enterobacteriaceae* in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). *Microb. Drug Resist.* 14: 211–216.

- Cattoir, V., L. Poirel, and P. Nordmann. 2007. Plasmid-mediated quinolone resistance determinant *qnrB4* identified in France in an *Enterobacter cloacae* clinical isolate coexpressing a *qnrS1* determinant. *Antimicrob. Agents Chemother.* 51: 2652–2653.
 - Cattoir, V., Nordmann, P., Silva- Sanchez, J. and Poirel, L. (2008). ISEcp1- mediated transposition of *qnrB*- like gene in *Escherichia coli*. *Antimicrob. Agents and Chemother.* 52: 2929-2932.
 - Cattoir, V., Poirel, L. and Nordmann, P. (2008). Plasmid-mediated quinolone resistance pump QepA2 in an *Escherichia coli* isolate from France. *Antimicrob. Agents Chemother.* 52: 3801–3804.
 - Cattoir, V., Poirel, L. Mazel, D., Soussy, C.-J. and Nordmann, P. (2007). *Vibrio splendidus* as the source of plasmid-mediated *qnrS*-like quinolone resistance determinants. *Antimicrob. Agents Chemother.* 51: 2650–2651.
 - Cattoir, V., Poirel, L., Aubert, C., Soussy, C. J. and Nordmann, P. (2008). Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental *Aeromonas* spp. *Emerg. Infect. Dis.* 14: 231–237.
 - Cavaco, L.M., Hasman, H., Xia, S. and Aarestrup, F.M. (2009). *qnrD*, a novel gene conferring transferable quinolone resistance in *Salmonella enterica* serovar Kentucky and Bovismorbificans strains of human origin. *Antimicrob Agents Chemother.* 53: 603-8.
- Chaudhary, K.P., Maurya, K.A., Jain, A., Sharma, N. and Mishra, A. (2015). Self medication practices with antibiotics among health care professional in Uttar pradesh, India. a questionnaire based study. *Indo American J of Pharm Research.* 5: 752-759.
- Chen X, Zhang W, Pan W, Yin J, Pan Z. (2012). Prevalence of *qnr*, *aac(6)-Ib-cr*, *qepA*, and *oqxAB* in *Escherichia coli* isolates from humans, animals, and the environment. *Antimicrob Agents Chemother.* 56: 3423-3427.

- Chen, L., Zhang, Y., Du, J., Zhang, X., Li, M., Chen, H., Yu, X., Sun, Y. and Zhou, T. (2016). Description and Plasmid Characterization of the *qnrD* Determinant in Proteae in Wenzhou, Southern China PII. *Journal of Microbiology, Immunology and Infection*. S1684-1182(16): 30001-9.
- Cheong, H., Yoo, C., Sohn, J., Kim, W., Kim, M. and Park, S. (2001). Bacteremia Due to Quinolone-Resistant *Escherichia coli* in a Teaching Hospital in South Korea. *Clinical Infectious Diseases*. 33: 48–53.
- Cheung, T.K., Chu, Y.W., Chu, M.Y., Ma, C.H, Yung, R.W. and Kam, K.M. (2005). Plasmid-mediated resistance to ciprofloxacin and ceftaxime in clinical isolates of *Salmonella enterica* serotype Enteritidis in Hong Kong. *J Antimicrob Chemother*. 56: 586-9.
- Chmelnitsky, I., Navon-Venezia, S., Strahilevitz, J. and Carmeli, Y. (2008). Plasmid-mediated *qnrB2* and carbapenemase gene *blaKPC-2* carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible *Enterobacter cloacae* isolates. *Antimicrob. Agents Chemother*. 52: 2962–2965.
- Chou, J.H., Greenberg, J.T. and Demple, B. (1993). Posttranscriptional repression of *Escherichia coli* OmpF in response to redox stress: positive control of the *micF* antisense RNA by the *soxRS* locus. *Jl of Bacteriol.*175: 1026–31.
- Chu, Y. W., Houang, E.T.S. and Cheng, A.F.B. (1998). Novel combination of mutations in the DNA-gyrase and topoisomerase IV genes in laboratory-grown fluoroquinolone-resistant *Shigella flexneri* mutants. *Antimicrob Agents and Chemother*. 42: 3051–2.
- Clinical Laboratory Standards Institute: Performance Standard for antimicrobial disc susceptibility test. 24th informational supplement . M100-S24. CLSI Wayne PA; (2014).
- Cohen, S.P., McMurry, L.M., Hooper, D.C., Wolfson, J.S. and Levy, S.B.(1998). Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) *Escherichia coli* selected by tetracycline or chloramphenicol: decreased drug accumulation associated with

membrane changes in addition to OmpF reduction. *Antimicrob Agents Chemother.* 33: 1318-25.

- Cohen, S.P., McMurry, L.M., Hooper, D.C., Wolfson, J.S. and Levy, S.B. (1989). Cross-resistance to fluoroquinolones in multiple antibiotic-resistant (Mar) *Escherichia coli* selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. *Antimicrob Agents and Chemother.* 33: 1318–25.
- Collee, J.G., Fraser, A.G. and Simmonus, A. (1996). Test for identification of in: Mackie & McCartney. Practical Medical microbiology, 14th. Churchill Livingstone in New York, USA.
- Collis, C.M. and Hall, R.M. (1995). Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. *Mol. Microbiol.* 15:593–600.
- Cordeiro, N.F., Robino, L., Medina, J., Seija, V., Bado, I., Garcia, V., Berro, M., Pontet, J., Lopez, L., Bazet, C., Rieppi, G., Gutkind, G., Ayala, J. A. and Vignoli, R. (2008). Ciprofloxacin-resistant enterobacteria harboring the *aac(6')-Ib-cr* variant isolated from feces of inpatients in an intensive care unit in Uruguay. *Antimicrob. Agents Chemother.* 52: 806–807.
- Critchlow, S.E., O’Dea, M.H., Howells, A.J., Couturier, M., Gellert, M. and Maxwell, A. (1997). The interaction of the F plasmid killer protein, CcdB, with DNA gyrase: induction of DNA cleavage and blocking of transcription. *J. Mol. Biol.* 273: 826–839.
- Cruz, G.R., Radice, M., Sennati, S., Pallecchi, L., Rossolini, G.M., Gutkind, G. and Di Conza, J.A. (2013). Prevalence of plasmid-mediated quinolone resistance determinants among oxyiminocephalosporin-resistant. *Mem Inst. Oswaldo Cruz.* 108(7): 924-927.
- Dalhoff, A. and Schmitz, F.J. (2003). *In vitro* antibacterial activity and pharmacodynamics of new quinolones. *Eur. J. Clin. Microbiol. Infect. Dis.* 22: 203-221.

- Dalhoff, A. (2012). Global fluoroquinolone resistance epidemiology and implications for clinical use. *Interdisc Perspect Infect Dis.* 2012: 1e37.
- Dana, E., King, M.D., Robb, M. and Sandra, H. (2000). New Classification and Update on the Quinolone Antibiotics, East Carolina University School of Medicine, Greenville, North Carolina. *Am Fam Physician.* 61(9): 2741-2748.
- Davis, R., Markham, A. and Balfour, J.A. (1996). Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. *Drugs.* 6: 1019–74.
- De Almeida, M.V., Saraiva M.F., De Souza, M.V.N., Da Costa C.F., Vincente F.R.C., Lourenco, M.C.S. (2007). *Bioorg. Med. Chem. Lett.* 17: 5661.
- Divya, M.P., Mathew, P.D., Jyothi, R., Bai, R. and Thomas, S. (2015). Mutations in *gyrA* & *parC* genes of *Shigella flexneri* 2a determining the fluoroquinolone resistance. *Indian J Med Res.* 141(6): 836–838. doi: [10.4103/0971-5916.160722](https://doi.org/10.4103/0971-5916.160722).
- Diwan, V., Chandran, S.P., Tamhankar, A.J., Stålsby Lundborg, C. and Macaden, R. (2012). Identification of extended-spectrum b-lactamase and quinolone resistance genes in *Escherichia coli* isolated from hospital wastewater from central India. *J Antimicrob Chemother.* 67: 857–859.
- Dollery, C. (1999). Norfloxacin, in *Therapeutic Drugs*, Churchill Livingstone, Harcourt Brace and Co. Ltd.: N137-N140.
- Domagala J.M. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials. *J. Antimicrob. Chemother.* 33 (4): 685.
- Drago, L., Nicola, L., Mattina, R. and De Vecchi, E. (2010). In vitro selection of resistance in *Escherichia coli* and *Klebsiella* spp. at *in vivo* fluoroquinolone concentrations. *BMC Microbiology.* 10:119.
- Drlica, K., Malik, M., Kerns, R. J. and Zhao, X. (2008). Quinolone mediated bacterial death. *Antimicrobial Agents and Chemotherapy.* 52 (2): 385–392.

- Drlica, K., and Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol. Mol. Biol. Rev.* 61: 377–392.
- Eckert, C., Gautier, V. and Arlet, G. (2006). DNA sequence analysis of the genetic environment of various blaCTX-M genes. *J. Antimicrob. Chemother.* 57: 14–23. 10.
- Eftekar, F. and Seyedpour, S.M. (2015). Prevalence of *qnr* and *aac(6′)-Ib-cr* Genes in Clinical Isolates of *Klebsiella Pneumoniae* from Imam Hussein Hospital in Tehran. Iran J Med. Science. 40 (6): 515-521.
- Eliopoulos, G.M. (2004). Quinolone resistance mechanisms in *pneumococci*. *Clin Infect Dis.* 38 (Suppl 4): S350-6.
- Ellington, M.J. and Woodford, N. (2006). Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure? *J. Antimicrob. Chemother.* 57: 1026–1029.
- Everett, M.J., Jin, Y.F., Ricci, V. and Piddock, L.J.V. (1996). Contribution of individual mechanisms to fluoroquinolone resistance in 36 *Escherichia coli* strains isolated from humans and animals. *Antimicrob Agents and Chemother.* 40: 2380–6.
- Fasching, C. E., Tenover, F. C., Slama, T. G., Fisher, L. M., Sreedharan, S., Oram, M., Willard, K., Sinn, L.M., Gerding, D. N., Peterson, L. R. (1991) *gyrA* mutations in ciprofloxacin-resistant, methicillin-resistant *Staphylococcus aureus* from Indiana, Minnesota, and Tennessee. *J. Infect. Dis.* 164: 976–979.
- Fasugba, O., Gardner, A., Mitchell, B.G. and Mnatzaganian, G. (2015). Ciprofloxacin resistance in community- and hospital-acquired *Escherichia coli* urinary tract infections: a systematic review and meta-analysis of observational studies. *BMC Infectious Diseases.* 15: 545
- Firoozeh, F., Zibaei, M. and Soleimani-Asl, Y. (2014). Detection of plasmid-mediated *qnr* genes among the quinolone-resistant *Escherichia coli* isolates in Iran. *J Infect Dev Ctries.* 8(7): 818-822.
- Fonseca, E. Dos Santos Freitas, L.F., Vieira, V.V. and Vicente. A.C. (2008). New *qnr* gene cassettes associated with superintegron repeats in *Vibrio cholerae* O1. *Emerg. Infect. Dis.* 14: 1129–1131.

- Fournier, B. and Hooper, D.C. (1998). Mutations in topoisomerase IV and DNA-Gyrase of *Staphylococcus aureus*: novel pleiotropic effects on quinolone and coumarin activity. *Antimicrob Agents and Chemother.* 42: 121–8.
- Francia, M.V., Varsaki, A.M., Barcia, P.G., Latorre, A., Drainas, C. And Cruz, F.D. (2004). A classification scheme for mobilization regions of bacterial plasmid. *FEMS Microbiol. Rev.* 28: 79-100.
- Frank, T., Mbecko, J.R., Misatou, P. and Monchy, D. (2011). Emergence of quinolone resistance among extended-spectrum beta-lactamase-producing Enterobacteriaceae in the Central African Republic: genetic characterization. *BMC Research Notes.* 4: 309.
- Freifeld A.G., Bow, E.J., Sepkowitz, K.A, Boeckh, M.J., Ito, J.I., Mullen, C.A., Raad, II., Rolston, K.V., Young, J.A. and Wingard, J.R. (2011). Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 52: 427-31.
- Freschi, C.R., Carvalho, L.F. and Bruno de Oliveira, C.J. (2005). Comparison of dna-extraction methods and selective enrichment broths on the detection of *Salmonella typhimurium* in swine faeces by polymerase chain reaction (PCR). *Brazilian Journal of Microbiol.* 36: 363-367.
- Friedman, S.M., Lu, T. and Drlica, K. (2001). Mutation in the DNA gyrase A gene of *Escherichia coli* that expands the quinolone resistance-determining region. *Antimicrob Agents Chemother.* 45: 2378-80.
- Fu, Y., Zhang, W. and Wang, H. (2013). Specific patterns of *gyrA* mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infectious Diseases.* 13(1), article 8.
- Fukuda., H. and Hiramatsu, K. (1999). Primary Targets of Fluoroquinolones in *Streptococcus pneumoniae*. *Antimicrob. agent and Chemother.* 43(2): 410–412.

- Fung-Tomc, J., Minassian, B., Kolek, B., Washo, T., Huczko, E. and Bonner, D. (2000). *In vitro* antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. *J. Antimicrob. Chemother.* 45: 437–446.
- Gaash, B. (2008). Irrational use of antibiotics. *Indian journal of practicing doctor.* 5(1): 25-29.
- Gallini, A., Degris, E., Desplas, M., Bourrel, R., Archambaud, M., Montastruc, J.L., Mestre, M.L. and Sommet, A. (2010). Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant *Escherichia coli* in a university hospital. *J Antimicrob Chemother.* 65: 2650-2657.
- Garrido, M.C., Herrero, M., Kolter, R. and Moreno, F. (1988). The export of the DNA replication inhibitor microcin B17 provides immunity for the host cell. *EMBO J.* 7:1853–1862.
- Gay, K., Robiscek, A., Strahilevitz, J., Park, C.H., Jacoby, G., Barrett, T.J., Medulla, F., Chiller, T.M. and Hooper, D.C. (2006). Plasmid mediated quinolone resistance in non-Typhi serotypes of *Salmonella enterica*. *Clin. Infect. Dis.* 43: 297-304.
- Geetha, V.K., Harish, B.N., Srinivasan, R. and Yugendran, T. (2014). Plasmid-mediated quinolone resistance in typhoidal *Salmonellae*: A preliminary report from South India. *Indian Journal of Medical Microbiology.* 32(1): 31-34.
- Gensberg, K., Jin, Y. F. and Piddock, L. J. V. (1995). A novel gyrB mutation in a quinolone-resistant clinical isolate of *Salmonella typhimurium*. *FEMS Microbiology Letters.* 132: 57–60.
- Gharib, A.A. and Abd El-Aziz, N.K. (2013). Molecular Analysis of Quinolone Resistance-Determining Regions in Avian Pathogenic *Escherichia coli*. *Int. J. Advanced Research.* 1(8): 145-157.
- Giraud, E., Brisabois, A., Martel, J. L. and Chaslus-Dancla, E. (1999). Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of *Salmonella* spp.

suggest a counterselection of highly fluoroquinolone-resistant strains in the field. *Antimicrob Agents Chemother.* 43: 2131–2137.

- Griggs, D.J., Gensberg, K. and Piddock, L.J.V. (1996). Mutations in *gyrA* gene of quinolone-resistant *Salmonella* serotypes isolated from human and animals. *Antimicrob Agents and Chemother.* 40: 1009–13.
- Gu, B., Cao, Y., Pan, S., Zhuang, L., Yu, R., Peng, Z., Qian, H., Wei, Y., Zhao, L., Liu, G. And Tong, M. (2012). Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of *Shigella* between Europe- America and Asia-Africa from 1998 to 2009. *Journal Antimicrob. Agent.* 40 (1): 9-17.
- Gunell, M., Webber, M.A., Kotilainen, P., Lilly, A.J., Caddick, J.M., Jalava, J., Huovinen, P., Siitonen, A., Hakanen, A.J. and Piddock, L.J. (2009). Mechanisms of Resistance in Nontyphoidal *Salmonella enterica* Strains exhibiting a Nonclassical Quinolone Resistance Phenotype. *Antimicrobial Agents And Chemotherapy.* 53(9): 3832–3836.
- Guneyssel, O., Onur, O., Erdede, M., Dehizbasi, A. (2009). Trimethoprim/sulfamethoxazole resistance in urinary tract infections. *J. Emerg. Med.* 36: 338.
Hakanen, A., Kotilainen, P., Jalava, A., Siitonen, A. and Huovinen, P. (1999). Detection of decreased fluoroquinolone susceptibility in *Salmonellas* and validation of nalidixic acid screening test. *Journal of Clinical Microbiol.* 37: 3572–7.
- Hall, R.M. and Collis, C.M., Kim, M.J., Partridge, S.R., Recchia, G.D. and Stokes, H.W. (1995). Mobile gene cassettes and integrons in evolution. *Ann. N.Y. Acad. Sci.* 870: 68-80.
- Hansen, L.H., Johannesen, E., Burmolle, M., Sorensen, A.H. and Sorensen, S.J. (2004). Plasmid-encoded multidrug efflux pump conferring resistance to olaquinox in *Escherichia coli*. *Antimicrob Agents Chemother.* 48: 3332-7.
- Hansen, L.H., Johannesen, E., Burmolle, M., Sorensen, A.H. and Sorensen, S.J. (2004). Plasmid-encoded multidrug efflux pump conferring resistance to olaquinox in *Escherichia coli*. *Antimicrob. Agents Chemother.* 48: 3332–3337.

- Hart, C. A. and Kariuki, S. (1998). Antimicrobial resistance in developing countries. *British Medical Journal*. 317: 647–50.
- Hashemi, S.H., Ashari, F.E., Tavakoli, S., Mojgan Mamani, M. (2013). The Prevalence of Antibiotic Resistance of Enterobacteriaceae Strains Isolated in Community- and Hospital-Acquired Infections in Teaching Hospitals of Hamadan, West of Iran. *Journal of Research Health Sc.* 13(1): 75-80.
- Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., Ibe, S. and Sakae, K. (2005). Cloning of a novel gene for quinolone resistance from a transferable plasmid in *Shigella flexneri* 2b. *Antimicrob. Agents Chemother.* 49: 801–803.
- Hawkey, P.M. (2003). Mechanism of quinolone action and microbial response. *J Antimicrob. Chemother.* 51(Suppl. S1): 29–35.
- Hazra, A. (2014). Schedule H1. Hope or hype. *Indian Journal of Pharmacology*. 46(4): 361-362.
- Heddle, J. G., Blance, S.J., Zamble, D.B.F. Hollfelder, D., Miller, A., Wentzell, L.M., Walsh, C. T. and Maxwell. A. (2001). The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. *J. Mol. Biol.* 307: 1223–1234.
- Hees, B.C., Tersmette, M., Willems, R.J.L., Jong, B., Biesma, D. and Hannen, E.J. (2011). Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical *Escherichia coli* isolates from haematology patients receiving ciprofloxacin prophylaxis. *J Antimicrob Chemother.* 66: 1739 –1744.
- Hegde, S. S., Vetting, M.W., Roderick, S.L., Mitchenall, L.A., Maxwell, A., Takiff, H.E. and Blanchard. J.S. (2005). A fluoroquinolone resistance protein from *Mycobacterium tuberculosis* that mimics DNA. *Science* 308: 1480–1483.
- Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in *Escherichia coli*. *Antimicrob Agents and Chemother.* 40: 879–885.
- Heisig, P. (2009). Type II topoisomerases—Inhibitors, repair

mechanisms and mutations. *Mutagenesis*. 24: 465–469.

<http://dx.doi.org/10.1155/2012/976273>. Article ID 976273.

- Helinski, D.R. (2004). Introduction to plasmids: a selective view of their history. In 371 B.E Funnell, and G.J.Philip (ed.), *Plasmid biology*. ASM Press, Washington, DC. 1-21.
- Hirai, K., Aoyama, H., Irikura, T., Iyobe, S. and Mitsuhashi, S. (1986). Difference in susceptibility to quinolones of outer membrane mutants of *Salmonella typhimurium* and *Escherichia coli*. *Antimicrob Agents and Chemother*. 29: 535–8.
- Holanda, S.M., Araújo, A., Filho, M.P.P., Teixeira de Figueiredo, J., Carvalho de Oliveira, L., Bruna do Vale, F., Ponte, A.C.B., Ramalho de Oliveira, J.G., Barros de Oliveira, M.R., Elizabeth De Francesco D. and Bezerra da Silva, G. (2015). Community-acquired urinary tract bacterial infections and drug resistance among patients followed at a reference center in Fortaleza, Ceará, Brazil. *Rev Patol Trop*. 44 (3): 245-257.
- Hooper D.C. (2003). Mechanism of quinolone resistance. In: Hooper DC, Rubinstein E, eds. *Quinolone Antimicrobial Agents*. 3rd ed. Washington, DC: American Society for Microbiology Press: 41-67.
- Hooper, D.C. (2000). Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones. *Clin Infect Dis*. 31(Suppl 2): S24–8.
- Hopper, D.C. and Wolfson, J.S. (1991). Fluoroquinolone antimicrobial agents. *N Engl J Med*. 324: 384-94.
- Iabadene, H., Messai, Y., Ammari, H., Ramdani-Bouguessa, N., Lounes, S., Bakour, R. and Arlet, G. (2008). Dissemination of ESBL and Qnr determinants in *Enterobacter cloacae* in Algeria. *J. Antimicrob. Chemother*. 62: 133–136.
- Iabadene, H., Messai, Y., Ammari, H., Ramdani-Bouguessa, N., Lounes, S., Bakour, S.R. and Arlet, G. (2008). Dissemination of ESBL and Qnr determinants in *Enterobacter cloacae* in Algeria. *J. Antimicrob. Chemother*. 62: 133–136.
- Ince, D. and Hooper, D.C. (2001). Mechanisms and frequency of resistance to gatifloxacin in comparison to AM1121 and ciprofloxacin in *Staphylococcus aureus*. *Antimicrob Agents and Chemother*. 45: 2755–64.

- Inderbinen, N.M., Abgottspon, H., Sagesser, G., Cernela, N. and Stephan, R. (2015). Antimicrobial susceptibility of travel-related *Salmonella enterica* serovar *Typhi* isolates detected in Switzerland (2002–2013) and molecular characterization of quinolone resistant isolates. *BMC Infectious Diseases*. 15: 212.
- Ishrat, J. A., Bijay, K. K., Akter, F., Hasan, T.N., Shahnaij, M., Akter, M., Banik, B., Sultana, H., Hossain, M.A., Ahmed, M.K., Faruque, S.M. and Talukder, K.A. (2014). Fluoroquinolone Resistance Mechanisms of *Shigella flexneri* Isolated in Bangladesh. *PLoS ONE* 9(7): e102533
- Islam, M.A., Huq, M., Nabi, A., Talukdar, P.K., Ahmed, D., Talukder, K.A., Cravioto, A. and Endtz, H.P. (2013). Occurrence and characterization of multidrug resistant New Delhi metallo- β -lactamase-1-producing bacteria isolated between 2003 and 2010 in Bangladesh. *Journal of Medical Microbiol.* 62: 62–68.
- Jacoby, G. A., Walsh, K. E., Mills, D. M., Walker, V. J., Oh, H., Robicsek, A. and Hooper, D. C. (2006). *qnrB*, another plasmid-mediated gene for quinolone resistance. *Antimicrob. Agents Chemother.* 50: 1178–1182.
- Jacoby, G., Cattoir, V., Hooper, D., Martínez-Martínez, L., Nordmann, P., Pascual, A., Poirel, L. and Wang, M. (2008). *qnr* gene nomenclature. *Antimicrob. Agents Chemother.* 52: 2297–2299.
- Jacoby, G.A. (2005). Mechanisms of resistance to quinolones. *Clin Infect Dis.* 41 (Suppl 2): S120-6.
- Jacoby, G.A., Gacharna, N., Black, T. A., Miller, G. H. and D. C. Hooper. (2009). Temporal appearance of plasmid-mediated quinolone resistance genes. *Antimicrob. Agents Chemother.* 53: 1665–1666.
- Jacoby, G.A., Walsh, K.E., Mills, D.M., Walker, V.J., Oh, H., Robicsek, A. and Hooper, D.C. (2006). *qnrB*, another plasmid-mediated gene for quinolone resistance. *Antimicrob Agents Chemother.* 50: 1178-82.
- Jaillon, P., Morganroth, J., Brumpt, I. and Talbot, G. (1996). Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. *J. Antimicrob. Chemother.* 37 (Suppl. A): 161–167.

- Jiang, Y., Pogliano, J., Helinski, D.R. and Konieczny, I. (2002). ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of *Escherichia coli* gyrase. *Mol. Microbiol.*44: 971–979.
- Jiang, Y., Zhou, Z., Qian, Y., Wei, Z., Yu, Y., Hu, S. and Li, L. (2008). Plasmid-mediated quinolone resistance determinants *qnr* and *aac(6⁷)-Ib-cr* in extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in China. *J. Antimicrob. Chemother.*61: 1003–1006.
- Jones, M. E., Sahm, D.F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C. et al. (2000). Prevalence of *gyrA*, *gyrB*, *parC*, and *parE* mutations in clinical isolates of *Streptococcus pneumoniae* with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997–1998 respiratory season. *Antimicrob Agents and Chemother.*44: 462–6.
- Jun, K.I., Koo, H.L., Kim, M.K., Kang, C.K., Kim, M.J., Chun, S.H., Song, J.S., Kim, H.S., Kim, N.J., Kim, E.C. and Oh, M.D. (2013). Trends in antibiotic use in a single university hospital. *Korean J Nosocomial Infect Control.* 18: 44-50.
- Jung, C. M., Heinze, T. M., Strakosha, R., Elkins, C. A. and Sutherland, J. B. (2009). Acetylation of fluoroquinolone antimicrobial agents by an *Escherichia coli* strain isolated from a municipal wastewater treatment plant. *J. Appl. Microbiol.* 106: 564–571.
- Kandel, S.M., El-Kader, A.A. and Mohamed, R.R. (2014). Prevalence of quinolone resistance among patients with urinary tract infection at Menoufia. *Menoufia Med. Journal.* 27(2): 440-446.
- Kaplan, E., Sela, N., Doron-Faigenboim, A., Navon-Venezia, S., Jurkevitch, E. and Cytryn, E. (2015) Genomic and Functional Characterization of *qnr*-Encoding Plasmids from Municipal Wastewater Biosolid *Klebsiella pneumoniae* Isolates. *Front Microbiol.* 6: 1354. doi: 10.3389/fmicb.2015.01354
- Keddy, K.H., Smith, A.M., Sooka, A., Ismail, H. and Oliver, S. (2010). Fluoroquinolone-resistant typhoid, South Africa. *Emerg Infect Dis.* 16: 879e880.

- Kehrenberg, C., Friederichs, S., Jong, A., Michael, G. B. and Schwarz, S. (2006). Identification of the plasmid-borne quinolone resistance gene *qnrS* in *Salmonella enterica* serovar Infantis. *J. Antimicrob. Chemother.* 58: 18–22.
 - Kehrenberg, C., Friederichs, S., Jong, and Schwarz, S. (2008). Novel variant of the *qnrB* gene, *qnrB12*, in *Citrobacter werkmanii*. *Antimicrob. Agents Chemother.* 52:1206–1207.
 - Kehrenberg, C., Hopkins, K.L. Threlfall, E.J. and Schwarz, S. (2007). Complete nucleotide sequence of a small *qnrS1*-carrying plasmid from *Salmonella enterica* subsp. *enterica* Typhimurium DT193. *J. Antimicrob. Chemother.* 60: 903–905.
 - Kim, J., Jeon, S., Kim, H., Lim, N., Park, M., Kim, S. and Seong- Han. (2012). Resistance to Fluoroquinolone by a Combination of Efflux and Target Site Mutations in Enteroaggregative *Escherichia coli* Isolated in Korea. *Osong Public Health Res Perspect.* 3(4), 239e244.
 - Kim, H.B., Wang, M., Ahmed, S., Park, C.H., LaRocque, R.C, Faruque, A.S., Salam, M.A., Khan, W.A., Qadri, F., Calderwood, S.B., Jacoby, G.A. and Hooper, D.C. (2010). Transferable quinolone resistance in *Vibrio cholerae*. *Antimicrob Agents Chemother.* 54: 799-803.
 - Kim, H.B., Wang, M., Park, C.H., Kim, E.C., Jacoby, G.A. and Hooper, D.C. (2009). *oqxAB* encoding a multidrug efflux pump in human clinical isolates of *Enterobacteriaceae*. *Antimicrob. Agents Chemother.* 53: 3582– 3584.
 - Koga, H., Itoh, A., Murayama, S., Suzue, S. and Irikura, T. (1980). Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline- 3-carboxylic acids. *J. Med. Chem.* 23: 1358- 1363.
- Koncan, R., Mazzariol, A. and Kocsis, B. (2010). First detection in Europe of plasmid-mediated fluoroquinolone resistance *qnrD* determinant. *Clin Microbiol Infect.* 16: S126.

- Kumagai, Y., Kato, J.I., Hoshino, K., Akasaka, T., Sato, K. and Ikeda, H. (1996). Quinolone-resistant mutants of *Escherichia coli* DNA Topoisomerase IV parC gene. *Antimicrob Agents and Chemother.* 40: 710–4.
- Kwak, Y.G., Truong-Bolduc, Q.C., Bin Kim, H., Song, K.H., Kim, E.S. and Hooper, D.C. (2013). Association of *norB* overexpression and fluoroquinolone resistance in clinical isolates of *Staphylococcus aureus* from Korea. *J Antimicrob Chemother.* 68: 2766- 72.
- Kwoh, S., Kellogg, D.E., McKinney, N., Spasic, D., Goda, L., Levenson, C. and Sninsky, J.J. (1990). Effects of primer-template mismatches on the polymerase chain reaction: human deficiency virus type 1 model studies. *Nucleic Acids Res.* 18:999–1005.
- Lascols, C., Podglajen, I., Verdet, C., Gautier, V., Gutmann, L., Soussy, C.J., Collatz, E. and Cambau, E. (2008). A plasmid-borne *Shewanella algae* gene, *qnrA3*, and its possible transfer in vivo between *Kluyvera ascorbata* and *Klebsiella pneumoniae*. *J. Bacteriol.* 190: 5217–5223.
- Lescher, G.Y., Froelich, E.J., Gruett, M.D., Bailey, J.H and Brundage, R.P. (1962). 1,8-Naphthyridine derivatives: a new class of chemotherapy agents. *J. Med. Pharm. Chem.* 5: 1063–1068.
- Levesque, C., Piche, L., Larose, C. and Roy, P.H. (1995). PCR Mapping of Integrons Reveals Several Novel Combinations of Resistance Genes. *Antimicrob agents Chemother.* 39(1): 185-191.
- Li, Bin., Yong Yi³., Qi Wang¹, Patrick C. Y. Tan, L., Jing ,H., Gao, G.F. and Liu, C.H. (2012). Analysis of Drug Resistance Determinants in *Klebsiella pneumoniae* Isolates from a Tertiary-Care Hospital in Beijing, China. *PLoS ONE.* 7(7): e42280.
- Liao, X., Fang, L., Li, L., Sun, J., Li, X., Chen, M., Deng, H., Yang, Q., Li, X. and Liua, Y. (2015). Characterization of Chromosomal *qnrB* and *ampC* Alleles in *Citrobacter freundii* Isolates from Different Origins. *Infection, Genetics and Evolution.* 35:214-20. doi: <http://dx.doi.org/10.1016/j.meegid.2015.07.011>
- Liassine, N., Zulueta-Rodriguez, P., Corbel, C., Lascols, C., Soussy, C. J. and Cambau, E. (2008). First detection of plasmid-mediated quinolone

resistance in the community setting and in hospitalized patients in Switzerland. *J. Antimicrob. Chemother.* 62: 1151–1152.

- Ling, J.M., Chan, E.W., Lam, A.W and Cheng, A.F. (2003). Mutations in Topoisomerase Genes of Fluoroquinolone-Resistant Salmonellae in Hong Kong. *J. Antimicrob. Chemother.* 47: 3567–3573. DOI: 10.1128/AAC.47.11.3567–3573.
 - Liu, B., Liao, X., Yang, S., Wang, X., Li, L., Sun, J., Yang, Y., Fang, L., Li, L., Zhao, D. and Liu, Y. (2012). Detection of mutations in the *gyrA* and *parC* genes in *Escherichia coli* isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. *Journal of Medical Microbiology.* 61: 1591–1599.
 - Lowe, M.N. and Lamb, H.M. (2000). Gemifloxacin. *Drugs.* 59: 1137–47.
 - Lui, J., Zeng, T., Su, G., Zhao, Y., Wang, W.Q., Xie, W.X., Zhao, Z.G. and Li, G.M. (2015). The dissemination of mode of drug- resistant genes in *Enterobacter cloacae*. *Indian Journal Med. Microbiol.* 33(5): 87-92.
 - Lunn, A.D., Fabrega, A., Sanchez- Cespedes, J., Vila, J. (2010). Prevalence of mechanisms decreasing quinolone susceptibility among *Salmonella* spp. clinical isolates. *Int. Microbiol.* 13: 15-20.
 - Ma, J., Zeng, Z., Chen, Z., Xu, X., Wang, X., Deng, Y., Lu, D., Huang, L., Zhang, Y., Liu, J. and Wang. M. (2009). High prevalence of plasmid-mediated quinolone resistance determinants *qnr*, *aac(6′)-Ib-cr*, and *qepA* among ceftiofur- resistant *Enterobacteriaceae* isolates from companion and food-producing animals. *Antimicrob. Agents Chemother.* 53: 519–524.
 - Ma, Z., Chu, D.T., Cooper, C.S., Li, Q., Fung, A.K., Wang, S., Shen, L.L., Flamm, R.K., Nilius, A.M., Alder, J.D., Meulbroek, J.A. and Or, Y.S. (1999). Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position. *J. Med. Chem.* 42: 4202–4213.
- Machado, E., Coque, T.M., Canto’n, R., Baquero, F., Sousa, J.C. and Peixe. L.(2006). Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM- 1-producing *Enterobacteriaceae* strains containing the *aac(6′)-Ib-*

cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme. *Antimicrob. Agents Chemother.* 50: 3220–3221.

- Magesh, H., Kamatchi, C., Vaidyanathan, R. and Sumathi, G. (2011). Identification of plasmid-mediated quinolone resistance genes *qnrA1*, *qnrB1* and *aac(6′)-Ib-cr* in a multiple drug-resistant isolate of *Klebsiella pneumoniae* from Chennai. *Indian journal of medical microbiology.* 29(3): 262-268.
- Mahamat, A., Daurès, J.P. and Sotto, A. (2005). Evaluation of the relation between consumption of fluoroquinolones and emergence of resistance among *Escherichia coli*: contribution of observational and quasi-experimental studies. *Med Mal Infect.* 35: 543-548. doi:10.1016/j.medmal.2005.06.007.
- Mainous, A.G., Diaz, V.A. and Carnemolla, M. (2008). Factors affecting Latino adults' use of antibiotics for self-medication. *J Am Board Fam Med.* 21(2):128-134.
- Malik, M., Zhao, X. and Drlica, K. (2006). Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. *Mol. Microbiol.* 61: 810–825.
- Mammeri, H., Poirel, L. and Nordmann, P. (2005). Bactericidal activity of fluoroquinolones against plasmid-mediated QnrA-producing *Escherichia coli*. *Clin. Microbiol. Infect.* 11: 1048–1049.
- Marti, E. and Balcázar, J.L. (2013). Real-Time PCR assays for quantification of *qnr* genes in environmental water samples and chicken faeces. *Appl Environ Microbiol.* 79: 1743-1745.
- Martínez-Martínez, L., Pascual, A. and Jacoby, G.A. (1998). Quinolone resistance from a transferable plasmid. *Lancet.* 351: 797–799.
- Matsumoto, M., Shigemura, K., Shirakawa, T., Nakano, Y., Miyake, H., Tanaka, K., Kinoshita, S., Arakawa, S., Kawabata, M. and Fujisawa, M. (2012). Mutations in the *gyrA* and *parC* genes and in vitro activities of fluoroquinolones in 114 clinical isolates of *Pseudomonas aeruginosa* derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography. *Inter Journal of Antimicrob Agents.* 40: 440–444.

- Matuz, M., Benko, R., Doro, R., Hajdu, E. and Soos, G. (2007). Non-prescription antibiotic use in Hungary. *Pharm World Sci.* 29: 695-698.
- Maurice, F., Broutin, I., Podglajen, I., Benas, P., Collatz, E. and Dardel, F. (2008) Enzyme structural plasticity and the emergence of broad-spectrum antibiotic resistance. *EMBO Rep.* 9: 344–349.
- Mazel, D. (2006). Integrons: agents of bacterial evolution. *Nature.* 4: 608- 620.
- Mine, T., Morita, Y., Kataoka, A., Mizushima, T. and Tsuchiya, T. (1999). Expression in *Escherichia coli* of a new efflux pump, MexXY, from *Pseudomonas aeruginosa*. *Antimicrob Agents and Chemother.* 43: 415–7.
- Mirarini, L.A.R., Poirel, L., Cattaoir, V., Darini, A.L.C. and Nordmann, P. (2008). Plasmid- mediated quinolone resistance determinants among enterobacterial isolates from outpatient in Brazil. *Journal of antimicrobial chemother.* 62: 474-478.
- Mitsuyama, J., Itoh, Y., Takahata, M., Okamoto, S. and Yasuda, T. (1992). In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of *Escherichia coli*, *Proteus mirabilis* and *Salmonella typhimurium*. *Antimicrob Agents and Chemother.* 36: 2030–6.
- Mizuchi, T., Wurtzel, E.T. and Inouye, M. (1996). Mechanism of bacteriophage Mu transposition. *Annu.Rev. Genet.* 20: 385-429.
- Mizuuchi, K., Fisher, L.M., O'Dea, M.H. and Gellert, M. (1980). DNA gyrase action involves the introduction of transient double-strand breaks into DNA. *Proc Natl Acad Sci.* 77: 1847–1851.
- Montastruc, J.L., Bagheri, H., Geraud, T., and Lapeyre-Mestre, M. (1997). Pharmacovigilance of selfmedication. *Therapie.* 52: 105-10.
- Montero, C., Mateu, G., Rodriguez, R. and Takiff, H. (2001). Intrinsic resistance of *Mycobacterium smegmatis* to fluoroquinolones may be influenced by new pentapeptide protein MfpA. *Antimicrob. Agents Chemother.* 45: 3387–3392.

- Murray, A., Mather, H., Coia, J. E. and Brown, D. J. (2008). Plasmid-mediated quinolone resistance in nalidixic-acid-susceptible strains of *Salmonella enterica* isolated in Scotland. *J. Antimicrob. Chemother.* 62: 1153–1155.
- Nakamura, S., Nakamura, M., Kojima, T. and Yoshida, H. (1989). *gyrA* and *gyrB* mutations in quinolone-resistant strains of *Escherichia coli*. *Antimicrob Agents and Chemotherapy.* 33: 254–5.
- Namboodiri, S.S., Opintan, J.A., Lijek, R.S., Newman, M.J. and Okeke, I.N. (2011). Quinolone resistance in *Escherichia coli* from Accra, Ghana. *BMC Microbiology.* 11: 44
- Nandihal, N.W. (2015). Profile of Urinary Tract Infection and Quinolone Resistance among *Escherichia coli* and *Klebsiella* species isolates.
- Nath, R., Saikia, L., Choudhury, G. and Sharma, D. (2013). Drug resistant *Shigella flexneri* in & around Dibrugarh, north-east India. *Indian J Med Res.* 137(1): 183–186.
- Nazik, H., Bektore, B., Ongen, B., Ilktaç, M., Ozyurt, M., Kuvat, N., Baylan, O., Keküllüoglu, H., Haznedaroglu, T. and Kelesoglu, F.M. (2011). Plasmid-Mediated Quinolone Resistance Genes in *Escherichia coli* Urinary Isolates from Two Teaching Hospitals in Turkey: Coexistence of TEM, SHV, CTX-M and VEB-1 Type β -lactamases. *Tropical Journal of Pharmaceutical Research.* 10(3): 325-333.
- Neuhauser, M.M., Weinstein, R.A., Rydman, R., Danziger, L.H., Karam, G. and Quinn, J.P. (2003). Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. *JAMA.* 289: 885-8.
- Ng, E.Y., Trucksis, M. and Hooper, D.C. (1996) Quinolone resistance mutations in topoisomerase IV: relationship to the *flqA* locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 40: 1881-8.

- Nishino, K. and Yamaguchi, A. (2001). Analysis of a complete library of putative drug transporter genes in *Escherichia coli*. *Jl of Bacteriol.* 183: 5803–12.
- Nordmann P, and Poirel L. (2005). Emergence of plasmid mediated resistance to quinolones in Enterobacteriaceae. *J. Antimicrob. Chemother.* 56:463-469.
- Norris, S. and Mandell, G.L. (1988). The quinolones: history and overview. In: Andriole VT (ed.) *The Quinolones*. Academic Press, San Diego. 1- 22
- Oethinger, M., Podglajen, I., Kern, W.V. and Levy, S.B. (1998). Overexpression of the *marA* or *soxS* regulatory gene in clinical topoisomerase mutants of *Escherichia coli*. *Antimicrob Agents and Chemother.* 42: 2089–94.
- Ogbolu, D.O., Daini, O.A., Ogunledun, A., Terry Alli, A.O., Olusoga-Ogbolu, F.F. and Webber, M.A. (2012). Effects of *gyrA* and *parC* Mutations in Quinolones Resistant Clinical Gram Negative Bacteria from Nigeria. *Afr. J. Biomed. Res.* 15: 97-104.
- Oktem, I.M.A., Gulay, Z., Bicmen, M., Gur,D. and the HITIT study group. (2008). *qnrA* Prevalence in Extended- Spectrum- Betalactamase-positive Enterobacteriaceae Isolates from Turkey. *Jpn.J.Infect Dis.* 61: 13-17.
- Pai, H., Seo, M. R. and Choi, T. Y. (2007). Association of *QnrB* determinants and production of extended-spectrum β -lactamases or plasmid-mediated AmpC β -lactamases in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 51: 366–368.
- Paiva, M.C., Nascimento, A.A., Camargo, I.B.C., Lima-Bittencourt, C.I. and Nardi, R.D. (2012). The first report of the *qnrB19*, *qnrS1* and *aac(6')-Ib-cr* genes in urinary isolates of ciprofloxacin-resistant *Escherichia coli* in Brazil. *Mem Inst Oswaldo Cruz.* 107(5): 687-689.
- Pallecchi, L., Riccobono, E., Mantella, A., Bartalesi, F., Sennati, S., Gamboa, H., Gotuzzo, E., Bartoloni, A. and Rossolini, G. M. (2009). High prevalence of *qnr* genes in commensal enterobacteria from healthy

children in Peru and Bolivia. *Antimicrob. Agents Chemother.* 53:2632–2635.

- Pandey, S.N. (2003). Antimicrobial Agents-Sulphonamides and Quinolones, in A Text Book of Medicinal Chemistry (Synthetic and Biochemical Approach). Mahavir Press, Bhelapur, S.G. Publisher, Varanasi. 547-585.
- Parimi, N., Pereira, L.M.P. and Prabhakar, P. (2004). Caregivers' practices, knowledge and beliefs of antibiotics in paediatric upper respiratory tract infections in Trinidad and Tobago: a cross-sectional study. *BMC Family Practice.* 5: 28.
- Park, Y.J., Yu, J. K., Lee, S., Oh, E.J. and Woo, G.J. (2007). Prevalence and diversity of *qnr* alleles in AmpC-producing *Enterobacter cloacae*, *Enterobacter aerogenes*, *Citrobacter freundii* and *Serratia marcescens*: a multicentre study from Korea. *J. Antimicrob. Chemother.* 60: 868–871.
- Partridge, S.R. and Hall, R.M. (2005). Evolution of transposons containing *bla*_{TEM} genes. *Antimicrob. Agents Chemother.* 49: 1267- 1268.
- Patel, M.M., Singh, U., Sapre, C., Salvi, K., Shah, A. and Vasoya, B. (2013). Self-medication practices among college students. A cross sectional study in Gujarat. *National J of medical research.* 3: 257-260.
- Pathak, A., Chandran, S.P., Mahadik, K., Macaden, R. and Lundborg, S. (2013). Frequency and factors associated with carriage of multi-drug resistant commensal *Escherichia coli* among women attending antenatal clinics in Central India. *BMC Infectious Dis.* 13: 199-207.
- Patrick, G.L. (2003). Antibacterial agents, in An Introduction to Medicinal Chemistry. Oxford University Press, Oxford, New York: 379-435.
- Pazhani, G.P., Chakraborty, S., Fujihara, K., Yamasaki, S., Ghosh, A., Nair, G.B. and Ramamurthy. T. (2011). QRDR mutations, efflux system & antimicrobial resistance genes in enterotoxigenic *Escherichia coli* isolated from an outbreak of diarrhoea in Ahmedabad, India. *Indian J Med Res.* 134(2): 214–223.

- Périchon, B., Courvalin, P. and Galimand, M. (2007). Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in *Escherichia coli*. *Antimicrob Agents Chemother.* 51: 2464-9.
- Périchon, B., Bogaerts, P., Lambert, T., Frangeul, L., Courvalin, P. and Galimand, M. (2008). Sequence of conjugative plasmid pIP1206 mediating resistance to aminoglycosides by 16S rRNA methylation and to hydrophilic fluoroquinolones by efflux. *Antimicrob. Agents Chemother.* 52:2581-2592.
- Picao, R.C., Poirel, L., Demarta, A., Silva, C.S., Corvaglia, A. R., Petrini, O. and Nordmann, P. (2008). Plasmid-mediated quinolone resistance in *Aeromonas allosaccharophila* recovered from a Swiss lake. *J. Antimicrob. Chemother.* 62: 948–950
- Picao, R.C., Poirel, L., Demarta, A., Silva, C.S., Corvaglia, A.R., Petrini, O. and Nordmann, P. (2008). Plasmid-mediated quinolone resistance in *Aeromonas allosaccharophila* recovered from a Swiss lake. *J. Antimicrob. Chemother.* 62: 948–950.
- Piddock, L.J.V. (1998). Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria. *Clin. Microbiol Rev.* 19; 2: 382-402.
- Pitout, J.D.D., Wei, Y., Church, D.L. and Gregson, D.B. (2008). Surveillance for plasmid-mediated quinolone resistance determinants in *Enterobacteriaceae* within the Calgary Health Region, Canada: the emergence of *aac(6′)-Ib-cr*. *J. Antimicrob. Chemother.* 61: 999–1002.
- Pohlhaus, J.R., Kreuzer, K.N.(2005). Norfloxacin-induced DNA-gyrase cleavage complexes block *Escherichia coli* replication forks, causing double-stranded breaks *in vivo*. *Mol. Microbiol.* 56: 1416–1429.
- Poirel, L., Cattoir, V. and Nordmann, P. (2012). Plasmid-Mediated Quinolone Resistance; Interactions between Human, Animal, and Environmental Ecologies. *Front Microbiol.* 3: 24.

- Poirel, L., Liard, A., Rodriguez-Martinez, J.M. and Nordmann. P. (2005). Vibrionaceae as a possible source of Qnr-like quinolone resistance determinants. *J. Antimicrob. Chemother.* 56: 1118–1121.
- Poirel, L., Rodriguez-Martinez, J. M., Mammeri, H., Liard, A. and Nordmann, P.(2005). Origin of plasmid-mediated quinolone resistance determinant QnrA. *Antimicrob. Agents Chemother.* 49: 3523–3525.
- Poirel, L., Van De Loo, M., Mammeri, H. and Nordmann. P. (2005). Association of plasmid-mediated quinolone resistance with extended-spectrum β lactamase VEB-1. *Antimicrob. Agents Chemother.* 49: 3091–3094.
- Pomba, C., D da Fonseca, J., Baptista, B.C., Correia, J.D. and Martínez-Martínez, L. (2009). Detection of the pandemic O25-ST131 human virulent *Escherichia coli* CTX-M-15-producing clone harboring the *qnrB2* and *aac(6′)-Ib-cr* genes in a dog. *Antimicrob. Agents Chemother.* 53: 327–328.
- Poole, K. (2005). Efflux-mediated antimicrobial resistance. *J Antimicrob Chemother.* 56: 20-51.
- Prakash, D. and Saxena, R.S. (2013). Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India. *Inter. Scholarly Research notices.* Article ID 749629: 1-13. <http://dx.doi.org/10.1155/2013/749629>
- Pu, X.Y., Pan, J.C., Wang, H.Q., Zhang, W., Huang, Z.C. and Gu, Y.M. (2009). Characterization of fluoroquinolone-resistant *Shigella flexneri* in Hangzhou area of China. *Journal of Antimicrob Chemother.* 63: 917–920.
- Putman, M., Van Veen, H.W. and Konings. W. N. (2000). Molecular properties of bacterial multidrug transporters. *Microbiol. Mol. Biol. Rev.* 64: 672–693.
- Quiroga, M. P., P. Andres, A. Petroni, A. J. Soler Bistue´, L. Guerriero, L. J. Vargas, A. Zorreguieta, M. Tokumoto, C. Quiroga, M. E. Tolmasky, M. Galas, and D. Centro´n. (2007). Complex class 1 integrons with diverse variable regions, including *aac(6′)-Ib-cr*, and a novel allele,

qnrB10, associated with *ISCR1* in clinical enterobacterial isolates from Argentina. *Antimicrob. Agents Chemother.* 51: 4466-4470.

- Ranjbar, R., Behnood, V., Memariani, Najafi A., Moghbeli, M. and Mamminad, C. (2016). Molecular characterisation of quinolone-resistant *Shigella* strains isolated in Tehran, Iran. *Journal of Global Antimicrobial Resistance.* 5: 26–30.
- Rath, S. and Padhy, R.N. (2015). Prevalence of fluoroquinolone resistance in *Escherichia coli* in Indian teaching hospital and adjoining communities. *Journal of Taibah university Medical Sciences.* 10(4): 504-508.
- Reyna, F., Huesca, M., Gonzalez, V. and Fuchs, L.Y. (1995). *Salmonella typhimurium* *gyrA* mutations associated with fluoroquinolone resistance. *Antimicrob Agents and Chemother.* 39: 1621–3.
- Ribera, A., Domenech-Sanchez, A., Ruiz, J., Benedí, V. J., Jiménez de Anta, M. T. and Vila, J. (2002). Mutations in *gyrA* and *parC* QRDRs are not relevant for quinolone resistance in *Stenotrophomonas maltophilia*.
- Ribera, A., Jurado, A., Ruiz, J., Marco, F., Del Valle, O., Mensa, J. (2002). In vitro activity of clinafloxacin in comparison with other quinolones against *Stenotrophomonas maltophilia* clinical isolates in the presence and absence of reserpine. *Diagnostic Microbiology and Infectious Dis.* 42: 123–8.
- Ribera, A., Ruiz, J., Jimenez de Anta, M.T. and Vila, J. (2002). Effect of an efflux pump inhibitor on the MIC of nalidixic acid for *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* clinical isolates. *Journal of Antimicrob Chemother.* 49: 697–8.
- Robicsek, A., Sahm, D. F., Strahilevitz, J., Jacoby, G. A. and Hooper, D. C. (2005). Broader distribution of plasmid-mediated quinolone resistance in the United States. *Antimicrob. Agents Chemother.* 49: 3001–3003.
- Robicsek, A., Strahilevitz, J., Jacoby, G.A., Macielag, M., Abbanat, D., Park, C.H., Bush, K. and Hooper, D.C. (2006). Fluoroquinolone modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat Med.* 12(1):83-8.

- Rodriguez-Martinez, J.M., Briales, A., Velasco, C., Conejo, M.C., Martinez- Martinez, L. and Pascual. A. (2009). Mutational analysis of quinolone resistance in the plasmid-encoded pentapeptide repeat proteins QnrA, QnrB and QnrS. *J. Antimicrob. Chemother.* 63: 1128–1134.
- Ruiz, E., Saenz, Y., Zarazaga, M., Rocha-Gracia, R., Martí'nez-Martí'nez, L., Arlet, G. and Torres, C. (2012). *qnr*, *aac(6')-Ib-cr* and *qepA* genes in *Escherichia coli* and *Klebsiella* spp.: genetic environments and plasmid and chromosomal location. *J Antimicrob Chemother.* 67(4): 886-97. doi:10.1093/jac/dkr548
- Ruiz, J., Casellas, S., Jimenez de Anta, M.T. and Vila, J. (1997). The region of the *parE* gene, homologous to the quinolone-resistant determining region of the *gyrB* gene, is not linked with the acquisition of quinolone resistance in *Escherichia coli* clinical isolates. *Journal of Antimicrob Chemother.* 39: 839–40.
- Ruiz, J., Castro, D., Goni, P., Santamaria, J. A., Borrego, J. J. and Vila, J. (1997). Analysis of the mechanism of quinolone-resistance in nalidixic acid-resistant clinical isolates of *Salmonella* serotype *Typhimurium*. *Journal of Medical Microbiol.* 46: 623–8.
- Ruiz, J., Goni, P., Marco, F., Gallardo, F., Mirelis, B., Jiménez de Anta, M.T. (1998). Increased resistance in *Campylobacter jejuni*. A genetic analysis of *gyrA* gene mutation in ciprofloxacin resistant clinical isolates. *Microbiology and Immunology.* 42: 223–6.
- Sabtcheva, S., Kaku, M., Saga, T., Ishii, Y. and Kantardjiev, T. (2009). High prevalence of the *aac(6')-Ib-cr* gene and its dissemination among *Enterobacteriaceae* isolates by CTX-M-15 plasmids in Bulgaria. *Antimicrob. Agents Chemother.* 53: 335–336.
- Saga, T., Kaku, M., Onodera, Y., Yamachika, S., Sato, K. and Takase, H. (2005). *Vibrio parahaemolyticus* chromosomal *qnr* homologue VPA0095: demonstration by transformation with a mutated gene of its potential to reduce quinolone susceptibility in *Escherichia coli*. *Antimicrob. Agents Chemother.* 49: 2144–2145.
- Sahoo, K.C. (2008). Antibiotic use, environment and antibiotic resistance: A qualitative study among human and veterinary health care

professionals in Orissa, India. Masters thesis in Applied Ecology: University of Halmstad School of Business and Engineering. Available from: URL: hh.diva-portal.org/smash/get/diva2:239095/FULLTEXT01

- Sanchez, M.B., Hernandez, A., Rodriguez-Martinez, J.M., Martinez-Martinez, L. and Martinez, J.L. (2008). Predictive analysis of transmissible quinolone resistance indicates *Stenotrophomonas maltophilia* as a potential source of a novel family of Qnr determinants. *BMC Microbiol.* 8: 148.
- Sangeeth, K., Ragesh, K.R. and Indrapriyadharsini, R. (2014). Antibiotic resistance pattern of *Escherichia coli* causing urinary tract infection with an emphasis on fluoroquinolone resistance. *Global J. Med Public health.* 3(1): 1-8.
- Sarkozy, G. (2001). Quinolones: a class of antimicrobial agents. *Vet. Med. Czech.* 46: 257.
- Schink, A., Kadlec, K. and Schwarz, S. (2012). Detection of qnr genes among *Escherichia coli* isolates of animal origin and complete sequence of the conjugative qnrB19-carrying plasmid pQNR2078. *J Antimicrob Chemother.* 1-4. doi:10.1093/jac/dks024
- Schmitz, F. J., Jones, M. E., Hofmann, B., Hansen, B., Scheuring, S. and Luckefarh, M. (1998). Characterization of grlA, grlB, gyrA and gyrB mutations in 116 unrelated isolates of *Staphylococcus aureus* and effects of mutations on ciprofloxacin MIC. *Antimicrob Agents and Chemother.* 42: 1249–52.
- Seija, Vero., Presentado, J. M., Bado, I., Ezdra, R. P., Batista, N., Gutierrez, C., Guirado, M., Vidal, M., Nn, M. and Vignoli, R. (2015). Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing *Morganella morganii*, treated successfully with fosfomycin and meropenem: case report and literature review. *Int. Journal of Infectious Diseases.* 30: 20–26.

- Sethuvel, D.P.M., Anandan, S., Ragupathi, N.D., Veeraraghavan, B., Vinod, O. and Walia, K. (2015). Association of blaCTX-M-15 and *qnr* genes in multidrug-resistant *Salmonella Typhimurium* and *Shigella* spp from India. *J Infect Dev Ctries.* 9(11): 1294-1297.
- Shao, Y., Xiong, Z., Li, X., Hu, L., Shen, J., Li, T., Hu, F. and Chen, S. (2011). Prevalence of plasmid-mediated quinolone resistance determinants in *Citrobacter freundii* isolates from Anhui province, PR China. *Journal of Med Microbiology.* 60: 1801–1805.
- Singh, R., Rajpara, N., Tak, J., Patel, A., Mohanty, P., Vinothkumar, K., Chowdhury, G., Ramamurthy, T., Ghosh, A. and Bhardwaj, A.S. (2012). Clinical isolates of *Vibrio fluvialis* from Kolkata, India, obtained during 2006: plasmids, the *qnr* gene and a mutation in gyrase A as mechanisms of multidrug resistance *Journal of Medical Microbiol.* 61: 369–374.
- Sjolund-Karlsson, M., Folster, J. P., Pecic, G., Joyce, K., Medalla, F., Rickert, R. and Whichard, J. M. (2009). Emergence of plasmid-mediated quinolone resistance among non-Typhi *Salmonella enterica* isolates from humans in the United States. *Antimicrob. Agents Chemother.* 53:2142–2144.
- Soge, O.O., Adeniyi, B.A. and Roberts, M.C. (2006). New antibiotic resistance genes associated with CTX-M plasmids from uropathogenic Nigerian *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.* 58:1048–1053.
- Somasundaram, S. and Manivannan, K. (2013). An Overview of Fluoroquinolones. *Ann Review Research in Biology.* 3(3): 296-313.
- Sørensen, A.H., Hansen, L.H., Johannesen, E. and Sørensen, S.J. (2003). Conjugative plasmid conferring resistance to olaquinox. *Antimicrob. Agents Chemother.* 47: 798–799.
- Sorlozano, A., Gutierrez, J., Jmenez, A., Luna, J. and Martinez, J.L. (2007). Contribution of new mutation in *parC* to quinolone resistance in extended spectrum- β -lactamase producing *Escherichia coli* isolates. *Journal of clinical microb.* 45: 2740-2742.

- Spangler, S.K., Jacobs, M.R. and Appelbaum, P.C. (1996). Susceptibility of anaerobic bacteria to trovafloxacin: comparison with other quinolones and non-quinolone antibiotics. *Infect. Dis. Clin. Pract.* 5 (Suppl. 3): S101–9.
- Strahilevitz, J., Jacoby, G.A., Hooper, D.C and Robicsek, A. (2009). Plasmid-mediated quinolone resistance: a multifaceted threat. *Clin Microbiol Rev.* 22: 664-89.
- Szabo, D., Kocsis, B., Rokusz, L., Szentandrassy, J., Katona, K., Kristof, K. and Nagy, K. (2008). First detection of plasmid-mediated, quinolone resistance determinants *qnrA*, *qnrB*, *qnrS* and *aac(6')-Ib-cr* in extended-spectrum lactamase (ESBL)-producing *Enterobacteriaceae* in Budapest, Hungary. *J. Antimicrob. Chemother.* 62: 630–632.
- Takei, M., Fukuda, H., Kishii, R. and Hosaka, M. (2001). Target preference of 15 quinolones against *Staphylococcus aureus* based on antibacterial activities and target inhibition. *Antimicrob Agents and Chemother.* 45: 3544–7.
- Takenouchi, T., Sakagawa, E. and Sugawara, M. (1999). Detection of *gyrA* mutations among 335 *Pseudomonas aeruginosa* strains isolated in Japan and their susceptibilities to fluoroquinolones. *Antimicrob Agents Chemother.* 43: 406–409.
- Talukdar, P.K., Rahman¹, M., Rahman, M., Nabi, A., Islam, Z., Hoque, M.M., Endtz, H.P. and Islam, M.A. (2013). Antimicrobial Resistance, Virulence Factors and Genetic Diversity of *Escherichia coli* Isolates from Household Water Supply in Dhaka, Bangladesh. *PLoS ONE.* 8(4): e61090.
- Tamang, M.D., Seol, S.Y., Oh, J.Y., Kang, H.Y., Lee, J.C., Cho, D.T. and Kim, J. (2008). Plasmid mediated quinolone resistance determinants *qnrA*, *qnrB* and *qnrS* among clinical isolates of Enterobacteriaceae in Korean hospital. *Antimicrob. Agents Chemother.* 52: 4159- 4162.
- Taneja, N., Mishra, A., Kumar, A., Verma, G. and Sharma, M. (2015). Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of *Shigella* due to synergism between efflux pump

expression & mutations in quinolone resistance determining region.
Indian J Med Res. 141: 81-89.

- Tarchouna, M., Ferjani, A., Marzouk, M., Guedda, I. and Boukadida, J. (2015). Prevalence of Plasmid-Mediated Quinolone Resistance Determinants among Clinical Isolates of *Escherichia coli* in a Tunisian Hospital. *Int.J.Curr.Microbiol.App.Sci.* 4(3): 195-206
- Tavio, M.M., Vila, J., Ruiz, J., Martin-Sanchez, A.M. and Jimenez de Anta, M.T. (1999). Mechanisms involved in the development of resistance to fluoroquinolones in *Escherichia coli* strains. *Journal of Antimicrobial Chemother.* 44: 735-42.
- Tenover, F.C. (2006). Mechanisms of antimicrobial resistance in bacteria. *Am. J. Med.* 119: S3-10.
- Thamizhmani, R., Bhattacharya, D., Sayi, D.S., Bhattacharjee, H., Muruganandam, N., Ghosal, S.R., Bharadwaj A.P., Singhanian, M., Roy, S. and Sugunan A.P. (2012). Emergence of fluoroquinolone resistance in *Salmonella enterica* serovar Typhi in Andaman and Nicobar Islands, India. *Indian J Med Res.* 136: 98-101.
- Thanassi, D.G., Cheng, L.W. and Nikaido, H. (1997). Active efflux of bile salts by *Escherichia coli*. *J Bacteriol.* 179: 2512-8.
- Thauvin-Eliopoulos, C. and Eliopoulos, G.M. Activity *in vitro* of the quinolones. In: Hooper DC, Rubinstein E, eds. *Quinolone Antimicrobial Agents*. 3rd ed. Washington, DC: American Society for Microbiology Press; 2003; 91-111.
- Thomas, C.M. (2000). Paradigms of plasmid organization. *Mol. Microbiol.* 37: 485-491.
- Tokue, Y., Sugano, K., Saito, D., Noda, T., Ohkura, H., Shimosato, Y., Sekiya, T. (1994). Detection of novel mutations in the *gyrA* gene of *Staphylococcus aureus* by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. *Antimicrob Agents Chemother.* 38(3): 428-31.

- Toleman, M. A., Bennett, P. M. and Walsh, T. R. (2006). ISCR elements: novel gene-capturing systems of the 21st century? *Microbiol. Mol. Biol. Rev.* 70: 296–316.
- Torniainen, K., Mattinen, J., Askolin, C.P. and Tammilehto, S. (1997). Structure elucidation of a photodegradation product of ciprofloxacin. *J. Pharm. Biomed. Anal.* 15: 887–894.
- Torpdahl, M., Hammerum, A.M., Zachariassen, C. and Nielsen, E.M. (2009). Detection of *qnr* genes in *Salmonella* isolated from humans in Denmark. *J. Antimicrob. Chemother.* 63: 406-408.
- Tripathi, A., Dutta, S.K., Majumdar, M., Dhara, L., Banerjee, D. and Roy, K. (2012). High Prevalence and Significant Association of ESBL and QNR Genes in Pathogenic *Klebsiella pneumoniae* Isolates of Patients from Kolkata, India. *Indian J Microbiol.* 52(4): 557–564.
- Valdezate, S., Vindel, A., Baquero, F. and Cantón, R. (1999). Comparative in vitro activity of quinolones against *Stenotrophomonas maltophilia*. *European Journal of Clinical Microbiol and Infectious Dis.* 18: 908–11.
- Valdezate, S., Vindel, A., Echeita, A., Baquero, F. and Canton, R. (2002). Topoisomerase II and IV quinolone resistance-determining regions in *Stenotrophomonas maltophilia* clinical isolates with different levels of quinolone susceptibility. *Antimicrob Agents and Chemother.* 46: 665–71.
- Van Elsas, J.D. and Bailey, M.J. (2002). The ecology of transfer of mobile genetic elements. *FEMS Microbiol. Ecol.* 42: 187-197.
- Van Hees, B.C., Tersmette, M., Willems, R.J.L., Ben de Jong, B., Biesma, D. and Van Hannen, E.J. (2011). Molecular Analysis of Ciprofloxacin Resistance and Clonal Relatedness of Clinical *Escherichia Coli* Isolates From Haematology Patients Receiving Ciprofloxacin Prophylaxis. *J Antimicrob Chemother.* 66 (8): 1739-1744.
- Velasco, C. Francia, M. V. and Martí'nez-Martí'nez, L. (2009). Detection of Plasmid-Mediated Quinolone Resistance Genes in Clinical Isolates of *Enterobacter* spp. in Spain. *Journal of Clinical Microbiol.* 2033–2039 .

- Veldman, K., Van Pelt, W. and Mevius, D. (2008). First report of *qnr* genes in *Salmonella* in The Netherlands. *J. Antimicrob. Chemother.* **61**: 452–453.
- Venter, J.C., Remington, K., Heidelberg, J.F., Halpern, A. L., Rusch, D., Eisen, J. A., Wu, D., Paulsen, I., Nelson, K. E., Nelson, W., Fouts, D. E., Levy, S., Knap, A. H., Lomas, M. W., Nealson, K., White, O., Peterson, J., Hoffman, J., Parsons, R., Baden-Tillson, H., Pfannkoch, C., Rogers, Y.-H. and Smith. H. O. (2004). Environmental genome shotgun sequencing of the Sargasso Sea. *Science*.304: 66–74.
- Versalovic J, Koeuth T, and Lupski J.R. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Nucleic Acids Res* 1991; 19:6823–6831.
- Vetting, M.W., Hegde, S.S., Fajardo, J.E., Fiser, A., Roderick, S. L., Takiff, H.E. and Blanchard, J.S. (2006). Pentapeptide repeat proteins. *Biochemistry*. 45: 1–10.
- Vetting, M.W., Park, C.H. Hegde, S.S. Jacoby, G.A. Hooper, D.C. and Blanchard. J.S.(2008). Mechanistic and structural analysis of aminoglycoside N-acetyltransferase *AAC(6')-Ib* and its bifunctional, fluoroquinolone active *AAC(6')-Ib-cr* variant. *Biochemistry*. 47: 9825–9835.
- Vij,A.S., Chopra, S. and Sehgal, J. (2014). Two years retrospective study of antibiotic resistance pattern of uropathogens especially *Escherichia coli* in north india. *CIBTech Journal of Microbiol.* 3(2): 29-36.
- Vila, J., Ruiz, J. and Navia, M.M. (1999). Molecular bases of quinolone resistance acquisition in gram-negative bacteria. *Recent Research Developments in Antimicrobials and Chemother.* 3: 323–44.
- Vila, J., Ruiz, J., Goni, P. and De Anta, J.D. (1996). Detection of Mutations in *parC* in Quinolone-Resistant Clinical Isolates of *Escherichia coli*. *Antimicrob. agents and Chemother.* 40(2): 491-493.
- Vila, J., Ruiz, J., Goni, P., Marcos, M.A. and Jiménez de Anta, M.T. (1995). Mutations in the *gyrA* gene of quinolone-resistant clinical isolates of *Acinetobacter baumannii*. *Antimicrob Agents and Chemother.* 39: 1201–3.

- Vila, J., Ruiz, J., Marco, F., Barceló, A., Goni, P., Giralt, E. (1994). Association between double mutation in *gyrA* gene of ciprofloxacin-resistant clinical isolates of *Escherichia coli* and minimal inhibitory concentration. *Antimicrob Agents and Chemother.* 38: 2477–9.
- Wain, J., Nguyen, T.T., Nguyen, T.C., Martin, H.V., Everett, M.J., Diep, T.S., Nicholas, P.J.D., Solomon, T., Nicholas, J.W., Piddock, L.J.V. and Parry, C.M. (1997). Quinolone-Resistant *Salmonella typhi* in Viet Nam: Molecular Basis of Resistance and Clinical Response to Treatment. *Clinical Infect Dis.* 25: 1404–10.
- Wang, H., Dzink-Fox, J.L., Chen, M. and Levy, S.B. (2001). Genetic characterization of highly fluoroquinolone-resistant clinical *Escherichia coli* strains from China: role of *acrR* mutations. *Antimicrob Agents Chemother.* 45: 1515-21.
- Wang, J.Y., Lee, L.N., Lai, H.C., Wang, S.K., Jan, I.S., Yu, C.J., Hsueh, P.R. and Yang, P.C. (2007). Fluoroquinolone resistance in *Mycobacterium tuberculosis* isolates: associated genetic mutations and relationship to antimicrobial exposure. *J Antimicrob Chemother.* 59 (5): 860-5.
- Wang, M., Guo, Q., Xu, X., Wang, X., Ye, X., Wu, S., Hooper, D.C. and Wang, M. (2009). New plasmid-mediated quinolone resistance gene, *qnrC*, found in a clinical isolate of *Proteus mirabilis*. *Antimicrob Agents Chemother.* 53: 1892-7.
Wang, M., Guo, Q., Xu, X., Wang, X., Ye, X., Wu, S., Hooper, D.C. and Wang, M. (2009). New plasmid mediated quinolone resistance gene, *qnrC1*, found in clinical isolates of *Proteus mirabilis*. *Antimicrob. Agents Chemother.* 53: 1892-1897.
- Wang, M., Sahm, D.F., Jacoby, G.A. and Hooper, D.C. (2004). Emerging plasmid-mediated quinolone resistance associated with the *qnr* gene in *Klebsiella pneumoniae* clinical isolates in the United States. *Antimicrob Agents Chemother.* 48: 1295-9.

- Wang, T., Tanaka, M. and Sato, K. (1998). Detection of *grlA* and *gyrA* mutations in 344 *Staphylococcus aureus* strains. *Antimicrob. Agents Chemother.* 42: 236-240.
- Wang, M., Tran, J.H., Jacoby, G.A., Zhang, Y., Wang, F. and Hooper, D.C. (2003). Plasmid-mediated quinolone resistance in clinical isolates of *Escherichia coli* from Shanghai, China. *Antimicrob Agents Chemother.* 47: 2242-8.
- Warburg, G., Korem, M., Robicsek, A., Engelstein, D., Moses, A.E., Block, C. and Strahilevitz, J. (2009). Changes in *aac(6⁺)-Ib-cr* prevalence and fluoroquinolone resistance in nosocomial isolates of *E. coli*: 1991–2005. *Antimicrob. Agents Chemother.* 53: 1268–1270.
- Watson, J.D. and Crick, F.H.C. (1953). Molecular structure of nucleic acid. *Nature.* 171: 737-738.
- Weigel, L.M., Steward, C.D. and Tenover, F.C. (1998). *gyrA* mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. *Antmicrob.agents and Chemother.* 42(10): 2661-2667.
- Wiedemann, B. and Heisig, P. (1997). Antibacterial activity of grepafloxacin. *J. Antimicrob. Chemother.* 40 (Suppl. A): 19–25.
- Wiegand, I., Luhmer-Becker, I. and Wiedemann, B. (2005). In vitro studies of oral ciprofloxacin doses: influence of plasmid-encoded fluoroquinolone resistance determinant *qnr*, abstr. A-448. Abstr. 45th Intersci. Conf. *Antimicrob. Agents Chemother.* American Society for Microbiology, Washington, DC
- Willmott, C.J. and Maxwell, A. (1993). A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. *Antimicrob Agents Chemother.* 37: 126-7.
- Wise, R. (1984). Norfloxacin – a review of pharmacology and tissue penetration. *J. Antimicrob. Chemother.* 13 (Suppl. B): 59–64.
- World Health Organization. Global strategy for Containment of Antimicrobial Resistance: World Health Organization, Communicable Disease surveillance and Response (CSR). WHO / CDS / CSR/ DRS / 2001.

- Wu, J.J., Ko, W.C., Tsai, S.H. and Yan, J.J. (2007). Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of *Enterobacter cloacae* in a Taiwanese hospital. *Antimicrob. Agents Chemother.* 51: 1223–1227.
- Xia, R., Guo, X., Zhang, Y. and Xu, H. (2010). *qnrVC*-like gene located in a novel complex class 1 integron harboring the ISCR1 element in an *Aeromonas punctata* strain from an aquatic environment in Shandong Province, China. *Antimicrob Agents Chemother.* 54: 3471-4.
- Yaiche, M.N., Rafraf, I.D., Guo, Q., Aouni, M.M. and Wang, M. (2014). Type II and type IV topoisomerase mutations in clinical isolates of *Morganella morganii* harbouring the *qnrD* gene. *Ann. of Clinical Microbiol. and Antimicrob.* 13: 34.
- Yamane, K., Wachino, J., Suzuki, S., Kimura, K., Shibata, N., Kato, H., Shibayama, K., Konda, T. and Arakawa, Y. (2007). New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an *Escherichia coli* clinical isolate. *Antimicrob Agents Chemother.* 51: 3354-60.
- Yamane, K., Wachino, J., Suzuki, S. and Arakawa, Y. (2008). Plasmid-mediated *qepA* gene among *Escherichia coli* clinical isolates from Japan. *Antimicrob. Agents Chemother.* 52:1564–1566.
- Yang, H., Chen, H., Yang, Q., Chen, M. and Wang, H. (2008). High prevalence of plasmid-mediated quinolone resistance genes *qnr* and *aac(6)-Ib-cr* in clinical isolates of *Enterobacteriaceae* from nine teaching hospitals in China. *Antimicrob. Agents Chemother.* 52: 4268–4273.
- Yonezawa, M., Takahata, M., Banzawa, N., Matsubara, N., Watanabe, Y. and Narita, H. (1995). Analysis of the NH₂-terminal 83rd amino acid of *Escherichia coli* GyrA in quinolone-resistance. *Microbiology and Immunology.* 39: 243–7.

- Yoshida, H., Bogaki, M., Nakamura, M. and Nakamura, S. (1990). Quinolone resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob Agents Chemother.* 34: 1271-1272.
Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. and Nakamura, S. (1991). Quinolone resistance-determining region in the DNA Gyrase *gyrB* gene of *Escherichia coli*. *Antimicrob Agents and Chemother.* 35: 1647–50.
- Yoshida, H., Bogaki, M., Nakamura, S., Ubukata, K. and Konno, M. (1990). Nucleotide sequence and characterization of the *Staphylococcus aureus* *norA* gene, which confers resistance to quinolones. *Jl of Bacteriol.* 172: 6942–9.
- Yoshida, H., Kojima, T., Yamagishi, J. L. and Nakamura, S. (1988). Quinolone-resistant mutations of the *gyrA* gene of *Escherichia coli*. *Molecular and General Genetics.* 211: 1–4.
- Yoshimura, F. and Nikaido, H. (1982). Permeability of *Pseudomonas aeruginosa* outer membrane to hydrophilic solutes. *Jl of Bacteriol.* 152: 636–42.
- Yugendran, T. and Harish, B.M. (2016). High incidence of plasmid-mediated quinolone resistance genes among ciprofloxacin-resistant clinical isolates of Enterobacteriaceae at a tertiary care hospital in Puducherry, India. *PeerJ PrePrints.* <https://doi.org/10.7287/peerj.preprints.1682v1>
- Zafar, S.N., Syed, R., Waqar, S., Zubairi, A.J., Vaqar, T., Shaikh, M., Yousaf, W., Shahid, S. and Saleem, S. (2008). Self-medication amongst University Students of Karachi: Prevalence, Knowledge and Attitudes. *J Pak Med Assoc. Student's corner.* 58(4):214-217.
- Zhanel, G.G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A.S., Embil, J., Smith, H. and Hoban, D.J. (2002). A critical review of the fluoroquinolones: focus on respiratory infections. *Drugs.* 62: 13–59.
- Zhanel, G.G., Hoban, D.J., Schurek, K. and Karlowisky, J.A. (2004). Role of efflux mechanisms on fluoroquinolone resistance in *Streptococcus pneumoniae* and *Pseudomonas aeruginosa*. *Int J Antimicrob Agents.* 24: 529-35.

- Zhao, X., Xu, C., Domagala, J. and Drlica, K. (1997). DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. *Proc. Natl. Acad. Sci. USA* 94: 13991–13996.
Zhao, Q., Li, X.Z., Srikumar, R. and Poole, K. (1998). Contribution of outer membrane efflux protein OprM to antibiotic resistance in *Pseudomonas aeruginosa* independent of MexAB. *Antimicrob Agents and Chemother.* 42: 1682–8.
- Zirnstein, G., Li, Y., Swaminathan, B. and Angulo F. (1999). Ciprofloxacin resistance in *Campylobacter jejuni* isolates: detection of *gyrA* resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis. *J Clin Microbiol.* 37: 3276–3280.